🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — April 14, 2026

Across 14 filings in the USA S&P 500 Technology stream, overarching themes include steady institutional portfolios (5/14 are 13Fs with no reported changes, heavy ETF and select tech exposure like Intel at $5.7B in Murphy Pohlad), governance shifts (board refreshes at ImmuCell, bylaw amendments at GameSquare, reverse split at Immunic), and mixed financials in non-core holdings (revenue declines at Saga Communications -5.1% YoY, loss narrowing at Bravo -41% expense cut). Period-over-period trends show deterioration in select areas: Saga's net operating revenue down 5.1% YoY to $107M with full goodwill impairment to $0, Bravo cash down 61% YoY to $111 amid 32% liability rise, but station expenses flat -0.1% at Saga. Critical developments include AParadise SPAC merger progress with Enhanced Ltd at $1.2B EV and May 1 meeting, ImmuCell's positive board bolstering animal health innovation, and Immunic's 1-for-10 reverse split effective April 27. Portfolio-level patterns reveal institutional conviction in tech outliers like Intel ($5.7B top holding) and Cisco ($1.5M), contrasting bearish signals from impairments and cash drains, signaling selective opportunities amid governance catalysts in May-June 2026.

6 high priority 8 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 14, 2026

Across 17 SEC filings from NASDAQ-100 stream companies and related entities on April 14, 2026, dominant themes include corporate governance shifts (Meta directors departing, ImmuCell board refresh with new Strategy Committee), high-profile M&A (Amazon's acquisition of Globalstar, AParadise SPAC merger with Enhanced at $1.2B EV), and mixed annual results (Saga revenue -5.1% YoY to $107M with $20M+ impairments driving net loss -$1.22 EPS vs +$0.55 prior; Bravo net loss improved 36% YoY to -$253K via 41% expense cuts but cash -61% to $111). Institutional 13F-HRs reveal stable, diversified ETF-heavy portfolios (e.g., Murphy Pohlad $279B AUM with Intel/Chevron tops, no changes noted). Period-over-period trends show media weakness (Saga flat expenses but market share dips in Milwaukee/Columbus) contrasting small-cap cost discipline (Bravo G&A -77% YoY); no broad insider trading signals but board changes signal potential strategy pivots. Forward catalysts cluster in May-June (SPAC votes, reverse splits, AGMs), with Amazon M&A implying telecom expansion amid neutral-to-positive sentiments (9/17 positive/mixed). Portfolio implications: Watch tech M&A for upside, media impairments for downside risks, governance for conviction gauges.

9 high priority 8 medium 17 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 14, 2026

Across 50 diverse SEC filings labeled under USA S&P 500 Financials (though spanning energy, healthcare, biotech, and industrials), key themes include a surge in M&A/takeover activity with attractive premiums (e.g., Avanos +72%, Day One $21.50/share), mixed Q1/FY results showing YoY revenue gains in banks like Wells Fargo (+6%) and Unity Bancorp (+12.8% NII) but QoQ softness and rising provisions, and neutral 13F holdings with no major shifts. Period-over-period trends reveal 6/12 earnings filings with YoY net income growth (avg +10%) offset by margin compression in 5/10 (avg -150bps, e.g., AstroNova -7.4% gross profit), while capital allocation favors dividends/buybacks (Unity +7%, Wells $4B repurchase). Forward-looking catalysts cluster in H2 2026 M&A closings and energy transition deals (DevvStream/XCF targeting $1B revenue). Portfolio-level, financials show loan/deposit growth (Unity +10.9%/+YoY) but credit provisions spiking (Wells +1095% YoY), signaling caution amid stable charge-offs. Implications: Tactical M&A arbitrage opportunities, monitor bank NIM/provisions, flat institutional conviction per 13Fs.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader financial and operational crossovers), dominant themes include strong YoY revenue and net income growth in major financial institutions like JPMorgan (+13% NI, +10% revenue), BlackRock (+27% revenue, $130B inflows), and Wells Fargo (+7% NI, +15% EPS), offset by rising credit provisions (Wells +1093% YoY) and mixed segment results. Consumer Staples highlights feature stable capital returns from Procter & Gamble (quarterly dividend $1.0885, record date Apr 24) and Hershey (exec departure neutral), alongside Celsius Holdings' steady 8.6-8.97% insider ownership amid proxy battles. Small-cap operators show sharp declines, e.g., Greystone Logistics sales -45% YoY 9M to $22M, Nature's Miracle revenue -97.6% YoY Q3, and Chipmos net profit -61.7% YoY amid margin compression to 10.8%. Portfolio-level trends reveal 4/7 key financial reporters with +6-27% YoY revenue growth but 3/5 with margin/operating pressures; capital allocation favors dividends (P&G, BlackRock +10%) and buybacks (Wells $4B, BlackRock $450M). Board/governance changes prevalent in 12/50 filings (e.g., appointments at ImmuCell, Invesco Mortgage), signaling strategic shifts. Actionable implications: Favor large-cap financials with consumer exposure for growth, monitor staples leadership stability and small-cap restatements for downside risks.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Industrials stream, 13F-HR reports dominate (e.g., Regent Peak, Runnymede, multiple American State Bank filings), revealing a portfolio-level pattern of heavy concentration in non-industrial mega-caps like Nvidia (top holding in 10+ filers, values up to $21.5M), Apple, and Microsoft, signaling institutional conviction in tech proxies amid industrial sector caution. Company-specific filings show mixed period-over-period trends: revenue growth in select areas (Heritage Distilling +20.4% YoY total net revenues, Unity Bancorp loans +10.9% YoY) contrasted by declines (Saga Communications -5.1% YoY revenue, Alphega net loss +92% YoY) and cash flow volatility (Antalpha financing cash -86% YoY). M&A activity surges in industrials-adjacent spaces like robotics (Serve Robotics acquisition complete, AgEagle $10M JV in counter-drones) and renewables (XCF Global/DevvStream/Southern merger targeting $1B revenue), with positive sentiment. Capital allocation mixed: dividend hikes (Unity +7% to $0.16, Ohio Valley $0.25) vs cuts (Saga -37.5% to $1.00). Forward-looking catalysts cluster in Q2 2026 AGMs (REGENXBIO May 29, Northrim May 28, ImmuCell June 11) and merger milestones (XCF $400M bonds, $1B revenue by Jun 30). Overall neutral-mixed sentiment (20+ neutral 13Fs), with actionable alpha in M&A execution risks and tech-tilted industrials exposure.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 14, 2026

Across the USA S&P 500 Energy intelligence stream, six filings highlight mixed sentiment dominated by operational volatility in APA Corp's preliminary 1Q26 results, showing robust international oil prices at $85.70/bbl and a $244M pre-tax net gain on purchases/sales, contrasted by negative US natural gas prices at $(0.35)/Mcf triggering 88 MMcf/d gas and 6,800 bbl/d NGL curtailments. OKMIN Resources reports a merger termination setback but secures $54k via dilutive private placement, while SunCoke Energy issues minor proxy corrections ahead of its May 14 AGM. Non-core filings include Silchester International's stable 13F-HR with $115.6B portfolio heavily tilted to non-energy names like Nutrien ($98.8B position), and AParadise Acquisition Corp's advancing $1.2B SPAC merger with Enhanced Ltd toward a May 1 vote and NYSE listing as ENHA. Limited period-over-period data reveals no broad YoY/QoQ trends across the group, but APA's elevated $115M G&A (incl. $25M higher stock-based comp) and $66M commodity derivative losses signal cost pressures amid price swings. Portfolio-level patterns point to May catalyst clustering (earnings, AGMs, votes) and M&A turbulence, with implications for near-term volatility in energy production and services amid US gas weakness versus international oil resilience.

3 high priority 3 medium 6 total filings
· daily

US Material Events SEC 8-K Filings — April 14, 2026

Across 50 8-K filings from April 14, 2026, dominant themes include a surge in M&A activity (8 deals: take-privates, mergers, JVs valued at >$2B total), extensive board/officer changes (25+ resignations/appointments, mostly neutral/positive for strategic alignment), and mixed financing events ($1.5B+ raised via equity/debt/credit but 4 distress signals). Period-over-period trends where disclosed show resilience (Assertio continuing ops revenue +9.7% YoY to $68.2M despite wider $31.3M net loss; no declines in 40/50 filings) but outliers like SunPower (GAAP revenue $300M down with margins -600bps to 43%) and Hydrofarm (interest default Jan 2026). Critical developments: Avanos 72% premium takeover ($1.27B EV), Lucid $750M funding+CEO shift, Horizon-Monroe BDC merger ($471M pro forma NA); bearish Hydrofarm forbearance, CERO dilutive note. Portfolio-level: Energy transition (6 filings) bullish on $1B+ rev targets; healthcare M&A active; BDCs consolidating. Implications: Arbitrage opps in deals, watch liquidity in small caps, positive capital alloc (Dow 459th div, CareCloud $3.2M savings).

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 14, 2026

Across 50 filings dated April 14, 2026, for the USA Dow Jones 30 stream, institutional 13F-HR reports (25+ filings) reveal overwhelming conviction in mega-cap tech with NVDA, AAPL, MSFT, and AMZN comprising top holdings in $100B+ portfolios, signaling sustained bullish bias amid no reported changes QoQ. Blue-chip earners show resilience: JNJ Q1 sales +9.9% YoY (raised FY2026 guidance to $100.8B, +7%), JPM net income +13% YoY ($16.5B), but mixed EPS/FCF trends (JNJ GAAP NI -52%). Healthcare catalysts dominate with Travere's first-ever FSGS FDA approval (46% proteinuria cut) and Avanos $1.27B buyout at 72% premium; energy M&A surges via XCF/DevvStream/Southern merger targeting $1B rev by Jun 30. Small caps flash distress: Hydrofarm loan forbearance post-default, Alphega loss +92% YoY, American Battery ICFR weaknesses. Capital allocation favors dividends (Unity +7%, Dow 459th consecutive $0.35, Ohio Valley $0.25). Portfolio trends: Revenue +10-20% YoY avg in reporters, but margins mixed (-7% gross AstroNova); DJ30-exposed names (JNJ, JPM, DOW) outperform small caps, implying buy blue-chips, avoid distressed.

17 high priority 33 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 14, 2026

Across 50 SEC filings for April 14, 2026, dominant themes include a surge in M&A activity particularly in biotech/healthcare (Avanos, Day One, Kezar) and energy transition (DevvStream/XCF/Southern mergers), mixed bank earnings with YoY growth but QoQ softness (Unity Bancorp +23% YoY NI, Wells Fargo +7% YoY), and revenue declines in small caps/industrials (Northann -11% YoY, SemiLEDs -90% YoY Q revenue). Period-over-period trends show 6/15 earnings filings with YoY revenue growth averaging +9% but QoQ mixed (-2% avg), margin compressions in 5/10 (avg -100bps), and positive capital returns like Unity's 7% dividend hike and Wells Fargo's $4B buyback. Neutral 13F filings (9 total) reveal persistent tech concentration (NVDA top in 4 portfolios). Critical developments: Travere's FDA approval for FILSPARI (46% proteinuria reduction), Westlake's $67M antitrust settlement, and Hydrofarm's debt forbearance signal sector risks. Portfolio-level: Healthcare M&A premiums average 70%+, energy backlog builds through 2030, but microcaps face restatements/declines; actionable now on catalysts like H2 2026 deal closes.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 14, 2026

Across 50 SEC filings from April 14, 2026, primarily non-Consumer Discretionary but including financials, energy, tech, and SPACs, key themes emerge in M&A activity (7 deals with positive/mixed sentiment), stable institutional 13F holdings heavily tilted to ETFs/tech (9 filings showing no changes), and mixed financial performance with revenue growth in 5/12 reporting companies (avg +27% YoY) offset by widening losses in development-stage firms. Period-over-period trends show YoY revenue gains (e.g., Full Truck Alliance +11.1%, Digital Brand Media +40.1% Q1) but margin pressures and rising provisions (Wells Fargo provisions +1094% YoY to $11.1B); capital allocation leans positive with dividend hikes (FNB +8%) and buybacks ($250M new program). Critical developments include merger closures (Horizon Technology positive) and distress signals (Hydrofarm forbearance, Gulf Resources 10-K delay), implying opportunities in consolidations but risks in liquidity-constrained names. Portfolio-level patterns: 6/10 financial filings bullish on returns to shareholders, contrasting negative debt events in 3 energy/industrials; no S&P 500 Consumer Discretionary pure-plays but cross-sector insights flag M&A as a growth driver amid stable institutional conviction.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, healthcare-specific insights reveal mixed Q1 2026 performance with Johnson & Johnson posting 9.9% YoY sales growth but 52.4% GAAP EPS decline, offset by raised FY2026 guidance (sales +7.0%, EPS +7.1%); biotech sector shows M&A momentum (Kezar tender at $6.955/share + CVR) and catalysts (Praxis NDA accepted, PDUFA Jan 29 2027). Aggregate trends indicate revenue acceleration in pharma (JNJ +9.9%, BeOne +40.2% YoY to $5.343B) but widening losses in pre-clinical biotechs (Accustem net loss +16.7% to $1.756M). Non-healthcare filings dominate (31/50 are 13F-HR neutral snapshots heavy in ETFs/tech like Apple/MSFT/NVDA, no changes), signaling advisor caution or stability; capital raises proliferate (Lucid $550M, Cingulate resale registration). Portfolio-level: 5/10 key healthcare firms raised/reiterated guidance, but 4/10 reported margin dips or expense surges (e.g., New Horizon R&D +867% YoY). Critical implications: Biotech alpha from catalysts/M&A, but dilution risks in small caps; watch advisor 13Fs for healthcare rotations.

12 high priority 38 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 14, 2026

Across 36 DEF 14A proxy statements filed around April 14, 2026, overarching themes include routine elections of directors (e.g., 100% board nominees in most cases), advisory say-on-pay votes, auditor ratifications (e.g., Deloitte, KPMG, E&Y dominant), and frequent amendments to equity incentive plans (e.g., increases in authorized shares for 10+ firms like EOSE, NSP, INSPIRE, ARBT) signaling aggressive talent retention amid 2025's mixed performance. Period-over-period trends show limited but telling data: bullish outliers like Equity Residential's 2.6% YoY Normalized FFO growth ($3.99/share), MyRisk volumes +10% at Myriad Genetics, and Brighthouse's audit fees +0.2% (stable), contrasted by bearish Mattel net sales -1% YoY, Flowers Foods' GAAP EPS $0.40 vs adjusted $1.09 (wide gap), and REGENXBIO's FDA clinical hold (Jan 2026) + CRL (Feb 2026). Sentiment is neutral-dominant (26/36), positive in 5 (EQR, MYGN, NRDS, ADT, TBI), mixed in 5; no widespread insider selling, with ownership guidelines met (e.g., Brighthouse directors hold 2,837-4,556 RSUs, no vested sales). Portfolio-level patterns: REITs outperform on growth (EQR top-quartile NOI +2.2%), biotechs face regulatory hurdles (3/5 mixed), consumer flat/declining; capital returns strong in EQR ($1.38B dividends/buybacks) and TrueBlue (19% share reduction via 6.7M repurchases). Critical implications: Annual meetings (May-June 2026 cluster) as catalysts for comp backlash or plan approvals; watch dilutive share hikes and SPAC liquidation risks for near-term volatility.

36 high priority 36 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 14, 2026

SRx Health Solutions, Inc. (SRXH) dominates the IPO Pipeline stream with its high-materiality (9/10) S-4 filing on April 14, 2026, signaling a pending business combination that could fast-track public listing via merger or de-SPAC structure. The filing discloses unaudited financials for FY2025 (2024-10-01 to 2025-09-30) and Q4 FY2025 (2025-10-01 to 2025-12-31) with prior-year comparatives across Digital, International, and Brick & Mortar revenue channels, highlighting diversification efforts amid customer concentration risks. Neutral sentiment prevails, balanced by crypto asset holdings (Ethereum, Bitcoin) and recent capital raises via private placement (2025-04-24). Key developments include the Halo SpinOut SPV Inc. transaction (2025-08-21) and Common Class A event (2025-04-25), underscoring restructuring for IPO readiness. No quantified period-over-period trends are detailed, but disclosures enable peer benchmarking in healthcare IPOs. Market implications point to near-term catalysts from merger completion, though dilution risks from convertible notes (issued 2025-07-07) and warrants loom large.

1 high priority 1 total filings
· daily

Global High-Priority Regulatory Events — April 14, 2026

Across 50 filings spanning April 14, 2026, a dominant theme is routine SEBI compliance from 18 Indian companies (e.g., Godavari Biorefineries, TD Power Systems) confirming non-Large Corporate status, signaling broad regulatory adherence among smaller/mid-cap firms with low outstanding borrowings (avg <₹100Cr where disclosed), reducing debt fundraising disclosure burdens. High-materiality US-centric events dominate actionability: Avanos Medical's $1.272B takeover at $25/share (72% premium), energy mergers (XCF/DevvStream/Southern targeting $1B rev/$100M EBITDA), contrasted by insolvencies (AGS Transact CIRP updates) and financial deteriorations (Northann rev -11.4% YoY, SemiLEDs -90% YoY). Period trends show mixed revenue (4/12 reporting firms up avg +12% YoY like Full Truck Alliance +11.1%, 5 down avg -35% YoY), pervasive margin compression (Chipmos -580bps to 10.8%, Immersion royalties -84.6% H1 YoY), and positive capital events (Dow 459th dividend, Shriram Fitch 'BBB-' upgrade post-MUFG stake). M&A/takeover volume (6 filings) implies sector consolidation in healthcare/energy, while IEPF defaults (Indian Hume Pipe, Jagsonpal) flag governance risks for unclaimed shareholders. Portfolio implications: overweight M&A targets, avoid distressed ops like Hydrofarm forbearance; catalyst-rich H2 2026 closes drive upside.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 14, 2026

Across 45 SEC filings in the Financial Results & Earnings stream (mostly 10-Q/10-K from small-cap US companies), overarching themes include widespread revenue declines (17/45 companies reported YoY drops averaging -40%, e.g., SemiLEDs -90%, Greystone -76%) and net loss expansions (25/45 widened losses YoY, avg +50%), offset by financing-driven cash boosts in 30+ cases and explosive growth outliers like BITMINE (+390% rev) and ABQQ (+236%). Mixed sentiment prevails (32/45), with SPACs (8 filings) stable via trust income (e.g., Legato IV +$686k net income from investments), while impairments (Saga $20M goodwill, Heritage $118M intangibles) and related-party reliance signal distress. Period trends show QoQ cash improvements in 20 companies (avg +50%) but margin compression (-150bps avg in 12 reporters) and dilution via share issuances (e.g., BITMINE shares doubled). No broad insider trading patterns, but capital allocation leans conservative (dividends cut in Saga -37.5%, Immersion declared $1.5M). Market implications: High volatility in microcaps, alpha in growth outliers amid sector rotation from cyclicals; portfolio caution on trade policy risks (Northann) and going concerns (Greystone, Go Go Buyers).

45 high priority 45 total filings
· daily

US SEC Trading Suspension Halt Orders — April 14, 2026

The single filing in the USA Trading Suspensions stream reveals acute delisting risk for Beasley Broadcast Group, Inc. (BBGI), which received a Nasdaq deficiency notice on April 13, 2026, for failing the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), reporting a $49,330,431 deficit in its December 31, 2025 Form 10-K. No period-over-period financial trends are detailed, but the deficit underscores severe balance sheet deterioration with no alternative listing standards met. Forward-looking risks emphasize no assurance of compliance plan approval by May 28, 2026, or extension to October 10, 2026, potentially leading to trading halt or delisting. Negative sentiment (10/10 materiality) dominates, signaling high portfolio risk for media/broadcast exposure. Investors face immediate implications for liquidity and valuation in suspension-prone small-caps, with ongoing trading under BBGI but elevated downside.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 14, 2026

Across 36 filings in the USA Corporate Distress & Bankruptcy intelligence stream (24 new), overarching themes reveal a financing frenzy with 18+ companies securing debt/equity (e.g., $50M CareCloud facility, $550M Lucid investment) to stave off liquidity crunches, contrasted by acute distress signals like Hydrofarm's interest default and Beasley's $49M stockholders' deficit triggering Nasdaq compliance risks. Period-over-period trends are sparse but highlight deteriorations: SunPower's GAAP revenue down $8.8M to $300M YoY with gross margins compressing 600 bps to 43%, Hydrofarm's unpaid interest due Jan 31 2026, and no broad margin expansions despite revenue targets like XCF's $1B fuel rev goal. M&A/take-private activity surges with premiums (Avanos 72%, Globalstar $90/share option), signaling exit opportunities amid distress, while 6 filings show covenant-heavy loans/forbearances maturing 2026-2027. Capital allocation leans toward deleveraging (CareCloud pref redemption saving $3.2M ann dividends) vs reinvestment, with no buybacks/dividends noted. Forward catalysts cluster H2 2026 (Avanos close, urban-gro 10-K filing), implying near-term volatility. Portfolio-level, neutral/positive sentiment dominates (26/36), but mixed/negative in 6 cases flag deepening distress; actionable now: arbitrage M&A spreads, short Nasdaq-deficient names.

36 high priority 36 total filings
· daily

US Executive Officer Management Changes SEC — April 14, 2026

Across 32 filings on US executive and director changes dated April 14, 2026, a dominant theme is proactive board and C-suite refreshes with experienced hires in growth sectors like energy, nuclear, biotech, and EV/autonomy, signaling strategic acceleration toward scaling, innovation, and profitability (e.g., Lucid's CEO hire, Oklo's nuclear experts, Corteva's crop protection CEO). Positive sentiments prevail in 16/32 filings (50%), with high-materiality appointments (8-9/10) in Lucid, Corteva, Harmony, and Invesco Mortgage emphasizing continuity and expertise amid planned successions. Neutral changes dominate resignations (18/32, no disagreements noted), but red flags emerge in mass director exits at Coretec Group (3 resignations) and finance terminations at XCF Global. Forward-looking catalysts include Harmony’s reiterated $1.0-1.04B 2026 revenue guidance, Spok’s $6M annual savings post-10% layoffs, Dow’s 459th consecutive dividend (Q2 payable June 12), and Corteva’s Q4 2026 spin-off with Sept 15 investor day. No broad YoY revenue/margin deterioration, but isolated mixed signals like Spok’s $1.6-2M Q2/Q3 charges highlight restructuring costs; overall, portfolio-level pattern favors bullish continuity in high-conviction sectors over isolated churn.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 14, 2026

Across 32 SEC 8-K filings on USA Board Room Changes (April 14, 2026), the dominant theme is leadership refresh with 18 resignations/departures (mostly neutral, no disagreements cited) and 20+ appointments/promotions of experienced executives/directors, signaling proactive governance evolution amid growth strategies. Positive developments cluster in high-materiality EV/nuclear (Lucid, Oklo), animal health (ImmuCell), and REITs (Invesco), with sentiments averaging positive/neutral (18 positive/mixed, 13 neutral, 1 negative). Capital allocation remains shareholder-friendly: Dow's 459th consecutive quarterly dividend ($0.35/share, record May 29, payable June 12), Spok's >10% yield maintained post-restructuring ($6M annual savings), Harmony's reiterated 2026 revenue guidance ($1.0-1.04B). No widespread period-over-period declines noted; outliers include Spok's Q2/Q3 2026 restructuring charges ($1.6-2M) vs savings. Portfolio implications: Bullish for sectors adding operational/scaling expertise (e.g., 6/10 high-materiality filings), monitor stability in microcaps with mass exits (Coretec); enhances conviction in continuity plays like Otter Tail's succession.

32 high priority 32 total filings
· daily

US Merger & Acquisition SEC Filings — April 14, 2026

The 13 filings reveal a surge in SPAC activity dominating USA M&A & Takeover space, with 3 new IPOs (Maywood, Apogee, ACP) raising ~$487M gross proceeds in early April 2026, alongside 2 de-SPAC completions (Horizon-Monroe merger closing with $471.7M pro forma assets; Haymaker-Suncrete despite pre-merger $31.5k net losses and going concern doubts). Key period trends include Assertio's pro forma continuing ops revenue +9.7% YoY to $68.2M (2025 vs 2024) but net loss widening 14.2% YoY to $31.3M, offset by $35M asset sale boosting cash to $45.2M and equity to $109.5M; discontinued ops showed $50.5M rev/$11.4M NI pre-sale. Positive sentiments prevail (7/13 positive/neutral), with Horizon announcing $10M buyback, supplemental distributions from July 2026, and $4M fee waivers. Portfolio-level patterns: SPAC fundraising liquidity up ~487M enabling targets in robotics/EVs/fintech; BDC consolidation via Horizon-Monroe adds $24B AUM. Implications: Heightened M&A catalysts short-term, watch SPAC deadlines (e.g., Suncrete July 28) and post-merger integrations for alpha.

13 high priority 13 total filings